Roving Reporter Asks: What’s the Most Exciting Research in CGT?
November 7, 2025
Experts discuss in vivo CAR T cell therapy, gene therapies for CNS diseases, personalized cancer vaccines and more.
1 min read
False
Advertisement
Cell & Gene
Integrity and Industry: Balancing Purpose and Profit
November 6, 2025
An invitation to our readers to feed back on our content
1 min read
From the Apollo Era to the World's First Cell Therapy: Sitting Down With Bruce Levine
November 5, 2025
Bruce Levine shares his journey from a childhood steeped in science to co-founding the first CAR T-cell trials, and explains why communication and regulatory collaboration are crucial for the field’s future.
7 min read
Roving Reporter Asks: What’s Your Tech Wishlist in CGT?
November 3, 2025
IBTV interviews 3 experts from the 2025 Cell & Gene Therapy Summit in London about advances in technology.
How To Optimize Batch Release for Advanced Therapies
November 3, 2025
For advanced therapies, every hour counts. The pressure on QA and QC teams is intense. How can automation ease the strain?
4 min read
Rise of the Robots: Scaling Up Cell Therapies in Small Spaces
October 29, 2025
Manual processes in cell therapy manufacturing are unsustainable. Bring in the robots.
3 min read
Cell and Gene Therapy: Hope, Hype and Political Upheaval
October 29, 2025
The cell and gene field has come a long way since the 1970s, but does political upheaval threaten progress?
1 min read
Hedgehogs, Seaweed, and the Future of Cell Logistics
October 24, 2025
How biology, sustainability, and a nod to the African pygmy hedgehog are reshaping how we move living cells around the world – and beyond.
6 min read
Roving Reporter Asks: What Are the Biggest Hurdles in Cell and Gene Therapy Development?
October 23, 2025
IBTV interviews show that funding and investment panic are dominating industry concerns.
The Cell & Gene Circuit: Keeping Up With Advancing Therapies and Technologies
October 22, 2025
Cell and gene therapy is advancing faster than ever, powered by breakthroughs in AI, automation, and CRISPR technology. But as some companies double down and others step back, the race to deliver real-world impact is intensifying.
4 min read